Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

AFP (Alpha-fetoprotein)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

Helio Liver Test

Helio Liver Test

›

AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2	sorafenib Sensitive: C2 – Inclusion Criteria sorafenib Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3	cabozantinib tablet Sensitive: C3 – Early Trials cabozantinib tablet Sensitive : C3
AFP elevation	Rectal Cancer	AFP elevation	Rectal Cancer	mFOLFOX6 Sensitive: C3 – Early Trials mFOLFOX6 Sensitive : C3	mFOLFOX6 Sensitive: C3 – Early Trials mFOLFOX6 Sensitive : C3
TERT mutation + AFP elevation	Hepatocellular Cancer	TERT mutation + AFP elevation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
AFP elevation	Prostate Cancer	AFP elevation	Prostate Cancer	etoposide IV + bleomycin Sensitive: C4 – Case Studies etoposide IV + bleomycin Sensitive : C4	etoposide IV + bleomycin Sensitive: C4 – Case Studies etoposide IV + bleomycin Sensitive : C4
AFP elevation + VIM positive	Sarcoma	AFP elevation + VIM positive	Sarcoma	doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Sensitive : C4	doxorubicin hydrochloride + ifosfamide Sensitive: C4 – Case Studies doxorubicin hydrochloride + ifosfamide Sensitive : C4
AFP expression	Solid Tumor	AFP expression	Solid Tumor	ACT-903 Sensitive: D – Preclinical ACT-903 Sensitive : D	ACT-903 Sensitive: D – Preclinical ACT-903 Sensitive : D